Abstract
OBJECTIVE: To evaluate the effect of dipeptidyl-peptidase-4 (DPP-4) inhibitor vildagliptin on high sensitivity C-reactive protein (hsCRP) and arterial stiffness (AS) in patients with type 2 diabetes (T2DM). DESIGN: Sixty-four drug-naive diabetic patients, with inadequate glycemic control, participated in this randomized, open-label study. Half of the patients received metformin 1700 mg/d and the other half of them received metformin 1700 mg/d plus vildagliptin 100 mg/d. AS was measured by carotid-femoral Pulse Wave Velocity (cfPWV). Body weight (BW), body mass index (BMI), blood pressure (BP), hsCRP, glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), lipid profile, albumin/creatinine ratio (ACR), fasting insulin, C-peptide, homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment of β-cell function (HOMA-β) were also assessed at baseline and after 6 months. RESULTS: Vildagliptin in combination with metformin had a beneficial influence on hsCRP, HbA1c, C-peptide and HOMA-β index (p <0.05) but had no effect on cfPWV, BP, BW, BMI, lipid profile, ACR and HOMA-IR compared with metformin alone (p=NS). CONCLUSIONS: We have found that the addition of vildagliptin to metformin for a period of six months decreased hsCRP, improved glycemic control and β-cell function but had no effect on AS in drug-naive patients with T2DM.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
King H, Aubert RE, Herman WH, 1998 Global burden of diabetes, 1995–2005. Prevalence, numerical estimates, projections. Diabetes Care 21: 1414–1431.
Brand FN, Abbot RD, Kannel WB, 1989 Diabetes, intermittent claudication and risk of cardiovascular events. The Framingham study. Diabetes 38: 504–509.
UK Prospective Diabetes Study (UKPDS) Group, 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.
Holman R, Retnakaran R, Farmer A, Stevens R, 2006 PROactive study. Lancet 367: 25–26.
Kieffer TJ, Habener JF, 1999 The glucagon-like peptides. Endocr Rev 20: 876–913.
Kieffer TJ, McIntosh CH, Pederson RA, 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585–3596.
Mu J, Woods J, Zhou YP, 2006 Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic b-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55: 1695–1704.
Ahrén B, 2008 Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 13: 593–607.
Nyström T, Gutniak MK, Zhang Q, et al, 2004 Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209–E1215.
Ban K, Noyan-Ashraf M, Hoefer J, Bolz SS, Drucker DJ, Husain M, 2008 Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340–2350.
Mari A, Sallas WM, He YL, et al, 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90: 4888–4894.
Derosa G, Ragonesi PD, Carbone A, et al, 2012 Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother 13: 2581–2591.
Shah Z, Kampfrath T, Deiuliis JA, et al, 2011 Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and Chemotaxis. Circulation 124: 2338–2349.
Van Poppel PC, Netea MG, Smits P, Tack CJ, 2011 Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 34: 2072–2077.
Boutouyrie P, Tropeano AI, Asmar R, et al, 2002 Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 39: 10–15.
Asmar R, Rudnichi A, Blacher J, London GM, Safar ME, 2001 Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens 14: 91–97.
Strandberg TE, Salomaa VV, Vanhanen HT, Pitkala K, Miettinen TA, 2002 Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years. J Hypertens 20: 399–404.
Roman MJ, Deveraux RB, Schwartz JE, et al, 2005 Arterial stiffness in chronic inflammatory diseases. Hypertension 46: 194–199.
Vlachopoulos C, Dima I, Aznaouridis K, et al, 2005 Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 112: 2193–2200.
Maki-Pataja KM, Booth AD, Hall FC, et al, 2007 Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50: 852–858.
The Reference Values for Arterial Stiffness Collaboration, 2010 Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 31: 2338–2350.
Mackenzie IS, Wilkinson IB, Cockroft J, 2002 Assessment of arterial stiffness in clinical practice. QJM 95: 67–74.
Friedewald WT, Levy RI, Fredrickson DS, 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
Pickup JC, Crook MA, 1998 Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–1248.
Tedesco MA, Natale F, Di Salvo G, Caputo S, Capasso M, Calabro R, 2004 Effects of coexisting hypertension and type II diabetes mellitus on arterial stiffness. J Hum Hypertens 18: 469–473.
Lee JM, Shirodaria C, Jackson CE, et al, 2007 Multimodal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 4: 44–48.
Van Der Meer RW, Diamant M, Westenberg JJ, et al, 2007 Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson 9: 645–651.
Theilade S, Lajer M, Persson F, Joergensen C, Rossing P, 2013 Arterial stiffness is associated with cardiovascular, renal, retinal and autonomic disease in type 1 diabetes. Diabetes Care 36: 715–721.
Keating GM, 2010 Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 70: 2089–2112.
Yin M, Silljé HH, Meissner M, Van Gilst WH, De Boer RA, 2011 Early and late effects of the DPP-4 inhibitor vildagliptin in rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 1186/1475-2840-10-85.
Shah Z, Pineda C, Kampfrath T, et al, 2011 Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 55: 2–9.
Matsui T, Nishino Y, Takeuchi M, Yamagishi S, 2011 Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 63: 383–388.
Derosa G, Maffiloi P, 2012 Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabet Technol Ther 14: 350–364.
Derosa G, Maffioli P, Ferrari I, et al, 2010 Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 42: 663–669.
Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockroft JR, Wilkinson IB, 2004 C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 24: 969–974.
Kim JS, Kang TS, Kim JB, et al, 2007 Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 192: 401–406.
Agarwal N, Rice SP, Bolusani H, et al, 2010 Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 95: 722–730.
Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H, 2005 Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 91: 589–594.
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ, 2007 Effects of vildagliptin on glucose control over 24 weekes in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890–895.
Ahren B, Pacini G, Tura A, Folley JE, Schweizer A, 2007 Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in type 2 diabetes. Horm Metab Res 39: 826–829.
Utzschneider KM, Tong J, Montgomery B, 2008 The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31: 108–113.
Vilsbøll T, 2007 Liraglutide: an once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 16: 231–237.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zografou, I., Sampanis, C., Gkaliagkousi, E. et al. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. Hormones 14, 118–125 (2015). https://doi.org/10.14310/horm.2002.1512
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1512